

WEST VIRGINIA LEGISLATURE

2025 REGULAR SESSION

Committee Substitute

for

House Bill 3343

By Delegate Worrell

[Originating in the Committee on Health and Human
Resources; Reported on March 20, 2025]

1 A BILL to amend and reenact §60A-2-204 of the Code of West Virginia, 1931, as amended,
2 relating to schedule I drugs; and adding a provision relating to the scheduling of crystalline
3 polymorph psilocybin approved by the Food and Drug Administration and the Drug
4 Enforcement Administration.

Be it enacted by the Legislature of West Virginia:

ARTICLE 2. STANDARDS AND SCHEDULES.

§60A-2-204. Schedule I.

1 (a) Schedule I shall consist of the drugs and other substances, by whatever official name,
2 common or usual name, chemical name, or brand name designated, listed in this section including
3 their isomers, esters, ethers, salts and salts of isomers, esters, and ethers, whenever the
4 existence of such isomers, esters, ethers, and salts is possible within the specific chemical
5 designation.

6 (b) Opiates.

7 Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl) -4-piperidiny]—
8 phenylacetamide);

9 Acetylmethadol;

10 Allylprodine;

11 Alphacetylmethadol (except levoalphacetylmethadol also known as levo-alpha-
12 acetylmethadol, levomethadyl acetate, or LAAM);

13 Alphameprodine;

14 Alphamethadol;

15 Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl] propionanilide;
16 1-(1-methyl-2-phenylethyl)-4-((propanilido) piperidine);

17 Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl) ethyl-4-piperidiny]—
18 phenylpropanamide);

19 Benzethidine;

- 20 Betacetylmethadol;
- 21 Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidiny]-N-
- 22 phenylpropanamide);
- 23 Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2- hydroxy-2-phenethyl)-3-methyl-4-
- 24 piperidiny]-N-phenylpropanamide);
- 25 Betameprodine;
- 26 Betamethadol;
- 27 Betaprodine;
- 28 Clonitazene;
- 29 Dextromoramide;
- 30 Diampromide;
- 31 Diethylthiambutene;
- 32 Difenoxin;
- 33 Dimenoxadol;
- 34 Dimepheptanol;
- 35 Dimethylthiambutene;
- 36 Dioxaphetyl butyrate;
- 37 Dipipanone;
- 38 Ethylmethylthiambutene;
- 39 Etonitazene;
- 40 Etoxidine;
- 41 Furethidine;
- 42 Hydroxypethidine;
- 43 Ketobemidone;
- 44 Levomoramide;
- 45 Levophenacymorphan;

- 46 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4- piperidyl]-N-phenylpropanamide);
- 47 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl) ethyl-4- piperidiny]—phenylpropanamide);
- 48 Morpheridine;
- 49 N-Methylnorfentanyl (N-(1-Methyl-4-piperidiny]-N-phenyl-propanamide,
- 50 monohydrochloride);
- 51 Norfentanyl (N-Phenyl-N-4-piperidiny]-propanamide);
- 52 MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 53 Noracymethadol;
- 54 Norlevorphanol;
- 55 Normethadone;
- 56 Norpipanone;
- 57 Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2- phenethyl)-4-piperidiny] propanamide);
- 58 PEPAP(1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 59 Phenadoxone;
- 60 Phenampromide;
- 61 Phenomorphan;
- 62 Phenoperidine;
- 63 Piritramide;
- 64 Proheptazine;
- 65 Properidine;
- 66 Propiram;
- 67 Racemoramide;
- 68 Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4- piperidiny]-propanamide);
- 69 Tilidine;
- 70 Trimeperidine.
- 71 (c) Opium derivatives,

- 72 Acetorphine;
- 73 Acetyldihydrocodeine;
- 74 Benzylmorphine;
- 75 Codeine methylbromide;
- 76 Codeine-N-Oxide;
- 77 Cyprenorphine;
- 78 Desomorphine;
- 79 Dihydromorphine;
- 80 Drotebanol;
- 81 Etorphine (except HCl Salt);
- 82 Heroin;
- 83 Hydromorphanol;
- 84 Methyldesorphine;
- 85 Methyldihydromorphine;
- 86 Morphine methylbromide;
- 87 Morphine methylsulfonate;
- 88 Morphine-N-Oxide;
- 89 Myorphine;
- 90 Nicocodeine;
- 91 Nicomorphine;
- 92 Normorphine;
- 93 Pholcodine;
- 94 Thebacon.
- 95 (d) Hallucinogenic substances.
- 96 Alpha-ethyltryptamine; some trade or other names: etryptamine; Monase; alpha-ethy-1H-
- 97 indole-3-ethanamine; 3-(2- aminobutyl) indole; alpha-ET; and AET;

98 4-bromo-2, 5-dimethoxy-amphetamine; some trade or other names: 4-bromo-2,5-
99 dimethoxy-alpha-methylphenethylamine; 4-bromo- 2,5-DMA;

100 4-Bromo-2,5-dimethoxyphenethylamine; some trade or other names: 2-(4-bromo-2,5-
101 dimethoxyphenyl)-1-aminoethane; alpha- desmethyl DOB; 2C-B, Nexus;

102 N-(2-Methoxybenzyl)-4-bromo-2, 5-dimethoxyphenethylamine. The substance has the
103 acronym 25B-NBOMe;

104 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C-NBOMe);
105 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe);

106 2,5-dimethoxyamphetamine; some trade or other names: 2,5-dimethoxy-alpha-
107 methylphenethylamine; 2,5-DMA;

108 2,5-dimethoxy-4-ethylamphet-amine; some trade or other names: DOET;

109 2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name: 2C-T-7);

110 4-methoxyamphetamine; some trade or other names: 4-methoxy-alpha-
111 methylphenethylamine; paramethoxyamphetamine; PMA;

112 3-Hydroxy-phencyclidine (other name hydroxy PCP);

113 5-methoxy-3, 4-methylenedioxy-amphetamine;

114 4-methyl-2,5-dimethoxy-amphetamine; some trade and other names: 4-methyl-2,5-
115 dimethoxy-alpha-methylphenethylamine; "DOM"; and "STP";

116 3,4-methylenedioxy amphetamine;

117 3,4-methylenedioxymethamphetamine (MDMA);

118 3,4-methylenedioxy-N-ethylamphetamine (also known as (ethyl-alpha-methyl-3,4
119 (methylenedioxy) phenethylamine, N-ethyl MDA, MDE, MDEA);

120 N-hydroxy-3,4-methylenedioxyamphetamine (also known as (hydroxy-alpha-methyl-3,4
121 (methylenedioxy) phenethylamine, and (hydroxy MDA);

122 3,4,5-trimethoxy amphetamine;

123 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);

- 124 Alpha-methyltryptamine (other name: AMT);
- 125 Bufotenine; some trade and other names: 3-(beta-Dimethylaminoethyl)-5-
- 126 hydroxyindole;3-(2-dimethylaminoethyl) -5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-
- 127 dimethyltryptamine; mappine;
- 128 Diethyltryptamine; some trade and other names: N, N-Diethyltryptamine; DET;
- 129 Dimethyltryptamine; some trade or other names: DMT;
- 130 5-Methoxy-N,N-disopropyltryptamine (5-MeO-DIPT);
- 131 Ibogaine; some trade and other names: 7-Ethyl-6, 6 Beta, 7, 8, 9, 10, 12, 13-octahydro-2-
- 132 methoxy-6, 9-methano-5H- pyrido [1', 2': 1, 2] azepero [5,4-b] indole; Tabernanthe iboga;
- 133 Lysergic acid diethylamide;
- 134 Marihuana; Marijuana (Cannabis, sp.);
- 135 Mescaline;
- 136 Parahexyl-7374; some trade or other names: 3-Hexyl -1-hydroxy-7, 8, 9, 10-tetrahydro-6,
- 137 6, 9-trimethyl-6H-dibenzo [b,d] pyran; Synhexyl;
- 138 Peyote; meaning all parts of the plant presently classified botanically as *Lophophora*
- 139 *williamsii* Lemaire, whether growing or not, the seeds thereof, any extract from any part of such
- 140 plant, and every compound, manufacture, salts, immediate derivative, mixture, or preparation of
- 141 such plant, its seeds or extracts;
- 142 N-ethyl-3-piperidyl benzilate;
- 143 N-methyl-3-piperidyl benzilate;
- 144 Psilocybin;
- 145 Psilocyn;
- 146 Tetrahydrocannabinols; synthetic equivalents of the substances contained in the plant, or
- 147 in the resinous extractives of *Cannabis, sp.* and/or synthetic substances, immediate derivatives
- 148 and their isomers with similar chemical structure and pharmacological activity including, but not
- 149 limited to the following:

150 delta-1 Cis or trans tetrahydrocannabinol, and their optical isomers;

151 delta-6 Cis or trans tetrahydrocannabinol, and their optical isomers;

152 delta-3,4 Cis or trans tetrahydrocannabinol, and its optical isomers;

153 delta-8 Cis or trans tetrahydrocannabinol and its optical isomers; and

154 delta-10 Cis or trans tetrahydrocannabinol and its optical isomers;

155 (Since nomenclature of these substances is not internationally standardized, compounds

156 of these structures, regardless of numerical designation of atomic positions covered.)

157 Delta-8-tetrahydrocannabinol-O (delta-8-THC-O), Delta-9-tetrahydrocannabinol (delta-9-
158 THC-O) and Synthetic and non-naturally occurring cannabinoids.

159 The provisions of this section related to tetrahydrocannabinols are inapplicable to products
160 or substances lawfully manufactured, distributed, or possessed under the provisions of §19-12E-
161 1 *et seq.* and Chapter 16H of this code.

162 Ethylamine analog of phencyclidine; some trade or other names: N-ethyl-1-
163 phenylcyclohexylamine, (1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine,
164 cyclohexamine, PCE;

165 Pyrrolidine analog of phencyclidine; some trade or other names: 1-(1-phenylcyclohexyl)-
166 pyrrolidine, PCPy, PHP;

167 Thiophene analog of phencyclidine; some trade or other names: 1-[1-(2-thienyl)-
168 cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine; TPCP, TCP;

169 1[1-(2-thienyl)cyclohexyl]pyrrolidine; some other names: TCPy;

170 4-methylmethcathinone (Mephedrone);

171 3,4-methylenedioxyprovalerone (MDPV);

172 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);

173 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);

174 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);

175 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);

- 176 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);
- 177 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);
- 178 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
- 179 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
- 180 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
- 181 3,4-Methylenedioxy-N-methylcathinone (Methylone);
- 182 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7, itsoptical isomers, salts and
183 salts of isomers;
- 184 5-methoxy-N,N-dimethyltryptamine some trade or other names: 5-methoxy-3-[2-
185 (dimethylamino)ethyl]indole; 5-MeO-DMT(5-MeO-DMT);
- 186 Alpha-methyltryptamine (other name: AMT);
- 187 5-methoxy-N,N-diisopropyltryptamine (other name: 5-MeO-DIPT);
- 188 Synthetic Cannabinoids as follows:
- 189 2-[(1R,3S)-3-hydroxycyclohexyl]-5- (2-methyloctan-2-yl)phenol {also known as CP
190 47,497 and homologues};
- 191 rel-2-[(1S,3R)-3-hydroxycyclohexyl] -5-(2-methylnonan-2-yl)phenol {also known as CP
192 47,497-C8 homolog};
- 193 [(6aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7,10,10a-
194 tetrahydrobenzo[c]chromen-1-ol] {also known as HU-210};
- 195 (dexanabinol);
- 196 (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
197 tetrahydrobenzol[c]chromen-1-ol {also known as HU-211};
- 198 1-Pentyl-3-(1-naphthoyl)indole {also known as JWH-018};
- 199 1-Butyl-3-(1-naphthoyl)indole {also known as JWH-073};
- 200 (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone {also known as JWH-015};
- 201 (1-hexyl-1H-indol-3-yl)-1-naphthalenyl-methanone {also known as JWH-019};

202 [1-[2-(4-morpholinyl) ethyl] -1H-indol-3-yl]-1-naphthalenyl-methanone {also known as
203 JWH-200};
204 1-(1-pentyl-1H-indol-3-yl)-2-(3-hydroxyphenyl)-ethanone {also known as JWH-250};
205 2-((1S,2S,5S)-5-hydroxy-2- (3-hydroxypropyl)cyclohexyl) -5-(2-methyloctan-2-yl)phenol
206 {also known as CP 55,940};
207 (4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl) -methanone {also known as JWH-122};
208 (4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl) -methanone {also known as JWH-398};
209 (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone {also known as RCS-4};
210 1-(1-(2-cyclohexylethyl) -1H-indol-3-yl) -2-(2-methoxyphenyl) ethanone {also known as
211 RCS-8};
212 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);
213 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201); and
214 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694).
215 Synthetic cannabinoids:
216 CP 47,497 AND homologues, 2-[(1R,3S)-3-Hydroxycyclohexyl]-5-(2-methyloctan-2-
217 YL)phenol);
218 HU-210, [(6AR,10AR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-Methyloctan-2-YL)-6A,7,10,
219 10A-tetrahydrobenzo[C] chromen-1-OL)];
220 HU-211, (dexanabinol, (6AS,10AS)-9-(hydroxymethyl)-6,6-Dimethyl-3-(2-methyloctan-2-
221 YL)-6A,7,10,10atetrahydrobenzo[C]chromen-1-OL);
222 JWH-018, 1-pentyl-3-(1-naphthoyl)indole;
223 JWH-019, 1-hexyl-3-(1-naphthoyl)indole;
224 JWH-073, 1-butyl-3-(1-naphthoyl)indole;
225 JWH-200, (1-(2-morpholin-4-ylethyl)indol-3-yl)- Naphthalen-1-ylmethanone;
226 JWH-250, 1-pentyl-3-(2-methoxyphenylacetyl)indole.]
227 Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (5F-

- 228 ADB);
- 229 Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F-AMB);
- 230 Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (FUB-
- 231 AMB);
- 232 N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA);
- 233 N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
- 234 (ADB-FUBINACA);
- 235 Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate
- 236 (MDMB-CHMICA);
- 237 Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (MDMB-
- 238 FUBINACA);
- 239 Tetrahydrocannabinols:
- 240 DELTA-1 CIS OR trans tetrahydrocannabinol and their Optical isomers.
- 241 DELTA-6 CIS OR trans tetrahydrocannabinol and their optical isomers.
- 242 DELTA-3,4 CIS or their trans tetrahydrocannabinol and their optical isomers.
- 243 Synthetic Phenethylamines
- 244 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe/ 2C-I-
- 245 NBOMe);
- 246 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe/2C-C-
- 247 NBOMe);
- 248 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe/ 2C-B-
- 249 NBOMe);
- 250 Synthetic Opioids (including their isomers, esters, ethers, salts and salts of isomers, esters
- 251 and ethers):
- 252 N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
- 253 furanyl fentanyl;

254 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as U-
255 47700);

256 N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, also known as N-(1-
257 phenethylpiperidin-4-yl)-N-phenylbutanamide, (butyryl fentanyl);

258 N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide, also known
259 as N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidiny]-N-phenylpropanamide, (beta-
260 hydroxythiofentanyl);

261 N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl);

262 N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl);

263 N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopropyl fentanyl);

264 2-(2,4-dichlorophenyl)-N-((1S,2S)-2-(dimethylamino)cyclohexyl)-N-methylacetamide
265 (also known as U-48800);

266 Trans-3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide (also known as
267 U-49900);

268 Trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzeneacetamide (also
269 known as U-51754);

270 2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine
271 (butonitazene);

272 2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine
273 (etodesnitazene);

274 N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine
275 (flunitazene);

276 N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine
277 (metodesnitazene);

278 N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine
279 (metonitazene);

280 2-(4-ethoxybenzyl)5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1 H-benzimidazole (N-
281 pyrrolidino etonitazene, etonitazepyne);

282 N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine
283 (protonitazene);

284 N-pyrrolidino etonitazene;

285 Etodesnitazene;

286 Isotonitazene;

287 Protonitazene;

288 Metonitazene;

289 Butonitazene;

290 Metodesnitazene;

291 Flunitazene;

292 Opioid Receptor Agonist

293 AH-7921 (3,4-dichloro-N-(1dimethylamino)cyclohexylmethyl]benzamide).

294 Naphthoylindoles or any compound containing a 3-(1-Naphthoyl) indole structure with
295 substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole
296 ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall
297 include the following:

298 JWH 015;

299 JWH 018;

300 JWH 019;

301 JWH 073;

302 JWH 081;

303 JWH 122;

304 JWH 200;

305 JWH 210;

306 JWH 398;
307 AM 2201; and
308 WIN 55,212.

309 Naphylmethylindoles or any compound containing a 1-indol-3-yl-(1-naphthyl) methane
310 structure with a substitution at the nitrogen atom of the indole ring whether or not further
311 substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to
312 any extent. This shall include, but not be limited to, JWH 175 and JWH 184.

313 Naphthoylpyrroles or any compound containing a 3-(1-Naphthoyl) pyrrole structure with
314 substitution at the nitrogen atom of the pyrrole ring whether or not further substituted in the pyrrole
315 ring to any extent and whether or not substituted in the naphthyl ring to any extent. This shall
316 include, but not be limited to, JWH 147 and JWH 307.

317 Naphthylmethylindenes or any compound containing a Naphthylideneindene structure
318 with substitution at the 3- Position of the indene ring whether or not further substituted in the
319 indene ring to any extent and whether or not substituted in the naphthyl ring to any extent. This
320 shall include, but not be limited to, JWH 176.

321 Phenylacetylindoles or any compound containing a 3- Phenylacetylindole structure with
322 substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole
323 ring to any extent and whether or not substituted in the phenyl ring to any extent. This shall include
324 the following:

325 RCS-8, SR-18 OR BTM-8;
326 JWH 250;
327 JWH 203;
328 JWH 251; and
329 JWH 302.

330 Cyclohexylphenols or any compound containing a 2-(3-hydroxycyclohexyl) phenol
331 structure with a substitution at the 5-position of the phenolic ring whether or not substituted in the

332 cyclohexyl ring to any extent. This shall include the following:

333 CP 47,497 and its homologues and analogs;

334 Cannabicyclohexanol; and

335 CP 55,940.

336 Benzoylindoles or any compound containing a 3-(benzoyl) indole structure with
337 substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole
338 ring to any extent and whether or not substituted in the phenyl ring to any extent. This shall include
339 the following:

340 AM 694;

341 Pravadoline WIN 48,098;

342 RCS 4; and

343 AM 679.

344 [2,3-dihydro-5 methyl-3-(4-morpholinylmethyl)pyrrolo [1,2,3-DE]-1, 4-benzoxazin-6-YL]-1-
345 naphthalenymethanone. This shall include WIN 55,212-2.

346 Dibenzopyrans or any compound containing a 11-hydroxydelta 8-tetrahydrocannabinol
347 structure with substitution on the 3-pentyl group. This shall include HU-210, HU-211, JWH 051,
348 and JWH 133.

349 Adamantoylindoles or any compound containing a 3-(-1- Adamantoyl) indole structure with
350 substitution at the nitrogen atom of the indole ring whether or not further substituted in the
351 adamantoyl ring system to any extent. This shall include AM1248.

352 Tetramethylcyclopropylindoles or any compound containing A 3-
353 tetramethylcyclopropylindole structure with substitution at the nitrogen atom of the indole ring
354 whether or not further substituted in the indole ring to any extent and whether or not substituted in
355 the tetramethylcyclopropyl ring to any extent. This shall include UR-144 and XLR-11.

356 N-(1-Adamantyl)-1-pentyl-1h-indazole-3-carboxamide. This shall include AKB48.

357 Any other synthetic chemical compound that is a Cannabinoid receptor type 1 agonist as

358 demonstrated by binding studies and functional assays that is not listed in Schedules II, III, IV, and
359 V, not federal Food and Drug Administration approved drug or used within legitimate, approved
360 medical research. Since nomenclature of these substances is not internationally standardized,
361 any immediate precursor or immediate derivative of these substances shall be covered.

362 Tryptamines:

363 5- methoxy- N- methyl-N-isopropyltryptamine (5-MeO-MiPT);

364 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);

365 4-hydroxy-N-methyl-N-isopropyltryptamine (4-HO-MiPT);

366 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);

367 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT);

368 5-methoxy- α -methyltryptamine (5-MeO-AMT);

369 4-methoxy-N,N-Dimethyltryptamine (4-MeO-DMT);

370 4-hydroxy Diethyltryptamine (4-HO-DET);

371 5- methoxy- N,N- diallyltryptamine (5-MeO-DALT);

372 4-acetoxy-N,N-Dimethyltryptamine (4-AcO DMT);

373 4-hydroxy Diethyltryptamine (4-HO-DET);

374 FDU-PB-22 (1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate);

375 FUB-PB-22 (Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate);

376 5-Fluoro-MN-24 (1-(5-Fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide);

377 MN-24 (N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide);

378 SDB-005 (Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate);

379 SDB-006 (1-Pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide);

380 Methyl-Ethylaminopentiophenone;

381 FUB-AMB (Methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate);

382 5-Fluoro-SDB-005 Indole (Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate);

383 5F-AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-

- 384 carboxamide);
- 385 MMB-CHMICA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-
- 386 methylbutanoat);
- 387 MN-24 (N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide);
- 388 SDB-005 (Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate);
- 389 SDB-006 (1-Pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide);
- 390 Ethcathinone (2-(ethylamino)-1-phenyl-1-propanone, monohydrochloride);
- 391 Methyl-Ethylaminopentiophenone;
- 392 FUB-AMB (Methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate);
- 393 5-Fluoro-SDB-005 Indole (Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate);
- 394 5F-AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-
- 395 3- carboxamide);
- 396 MMB-CHMICA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-
- 397 methylbutanoat);
- 398 Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);
- 399 Clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4 H-[1,2,4]triazolo[4,3-
- 400 a][1,4]benzodiazepine);
- 401 Cloniprazepam (5-(2-chlorophenyl)-1-(cyclopropylmethyl)-1,3-dihydro-7-nitro-2H-1,4-
- 402 benzodiazepin-2-one);
- 403 Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f] [1,2,4]triazolo[4,3-
- 404 a][1,4]diazepine);
- 405 Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-
- 406 a][1,4]benzodiazepine);
- 407 Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one);
- 408 Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-
- 409 a][1,4]benzodiazepine);

- 410 Flunitrazolam (6-(2-fluorophenyl)-1-methyl-8-nitro-4H-benzo[f][1,2,4]triazolo[4,3-
411 a][1,4]diazepine);
- 412 Nifoxipam (5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-7-nitro-2H-1,4-benzodiazepin-2-
413 one) ;
- 414 Nitrazolam (1-methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine); and
- 415 Pyrazolam (8-bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-
416 a][1,4]benzodiazepine).
- 417 (e) Depressants.
- 418 4-CN-CUMYL-BUTINACA (1-(4-Cyanobutyl)-N-(2-phenylpropan-2- yl)-1H-indazole-3-
419 carboxamide);
- 420 Alpha-Phenylacetoacetonitrile (3-Oxo-2-phenylbutanenitrile);
- 421 2-Fluoro Deschloroketamine (2-(2-Fluorophenyl)-2-(methylamino)-cyclohexanone,
422 monohydrochloride);
- 423 4-MEAP (2-(Ethylamino)-1-(4-methylphenyl)pentan-1-one);
- 424 Mecloqualone;
- 425 Methaqualone;
- 426 Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);
- 427 Clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4 H-[1,2,4]triazolo[4,3-
428 a][1,4]benzodiazepine);
- 429 Cloniprazepam (5-(2-chlorophenyl)-1-(cyclopropylmethyl)-1,3-dihydro-7-nitro-2H-1,4-
430 benzodiazepin-2-one);
- 431 Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f] [1,2,4]triazolo[4,3-
432 a][1,4]diazepine);
- 433 Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-
434 a][1,4]benzodiazepine);
- 435 Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one);

436 Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-
437 a][1,4]benzodiazepine);

438 Flunitrazolam (6-(2-fluorophenyl)-1-methyl-8-nitro-4H-benzo[f][1,2,4]triazolo[4,3-
439 a][1,4]diazepine);

440 Nifoxipam (5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-7-nitro-2H-1,4-benzodiazepin-2-
441 one);

442 Nitrazolam (1-methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);

443 Pyrazolam (8-bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-
444 a][1,4]benzodiazepine);

445 Declazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-
446 one); and

447 Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6H-thieno[3,2- f][1,2,4]triazolo[4,3-
448 a][1,4]diazepine);

449 (f) Stimulants.

450 Aminorex; some other names: aminoxaphen; 2-amino-5- phenyl-2-oxazoline; or 4,5-
451 dihydro-5-phenyl-2-oxazolamine;

452 Cathinone; some trade or other names: 2-amino-1-phenyl-1- propanone, alpha-
453 aminopropiophenone, 2-aminopropiophenone and norephedrone;

454 Fenethylamine;

455 Methcathinone, its immediate precursors and immediate derivatives, its salts, optical
456 isomers and salts of optical isomers; some other names: (2-(methylamino)-propiophenone; alpha-
457 (methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1- one; alpha—
458 methylaminopropiophenone; monomethylpropion; 3,4-methylenedioxypropylvalerone and/or
459 mephedrone; 3,4-methylenedioxypropylvalerone (MPVD); ephedrone; N-methylcathinone;
460 methylcathinone; AL-464; AL-422; AL- 463 and UR1432;

461 (+-) cis-4-methylaminorex; ((+)-cis-4,5-dihydro-4-methyl- 5-phenyl-2-oxazolamine);

- 462 N-ethylamphetamine;
- 463 N,N-dimethylamphetemine; also known as N,N-alpha- trimethyl-benzeneethanamine;
- 464 N,N-alpha-trimethylphenethylamine;
- 465 Alpha-pyrrolidinopentiophenone, also known as alpha-PVP, optical isomers, salts and
- 466 salts of isomers;
- 467 Substituted amphetamines:
- 468 2-Fluoroamphetamine;
- 469 3-Fluoroamphetamine;
- 470 4-Fluoroamphetamine;
- 471 2-chloroamphetamine;
- 472 3-chloroamphetamine;
- 473 4-chloroamphetamine;
- 474 2-Fluoromethamphetamine;
- 475 3-Fluoromethamphetamine;
- 476 4-Fluoromethamphetamine;
- 477 4-chloromethamphetamine;
- 478 Ethcathinone (2-(ethylamino)-1-phenyl-1-propanone, monohydrochloride);
- 479 Alpha-PHP (1-Phenyl-2-(pyrrolidin-1-yl)hexan-1-one);
- 480 MPHP (1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one);
- 481 PV8 (1-Phenyl-2-(pyrrolidin-1-yl)heptan-1-one);
- 482 4-Chloro-Alpha-PVP (1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one);
- 483 N-Ethylhexedrone (2-(Ethylamino)-1-phenylhexan-1-one);
- 484 Methoxetamine (2-(Ethylamino)-2-(3-methoxyphenyl)-cyclohexanone); and
- 485 3-Fluorophenmetrazine (2-(3-Fluorophenyl)-3-methylmorpholine);
- 486 (g) Temporary listing of substances subject to emergency scheduling. Any material,
- 487 compound, mixture, or preparation which contains any quantity of the following substances:

488 N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts,
489 and salts of isomers;

490 N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl), its optical
491 isomers, salts, and salts of isomers.

492 N-benzylpiperazine, also known as BZP;

493 Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);

494 4-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]-
495 butyramide);

496 Isobutyryl fentanyl (2-methyl-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-propanamide);

497 Methoxyacetyl fentanyl (2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-
498 acetamide);

499 3-methylbutyryl fentanyl (N-[3-methyl-1-(2-phenylethyl)piperidin-4-yl]-N-
500 phenylbutyramide);

501 4-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-
502 yl)butyramide);

503 Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]-acetamide);

504 Tetrahydrofuran fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-
505 carboxamide); and

506 Valeryl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]pentanamide).

507 (h) The following controlled substances are included in Schedule I:

508 Synthetic Cathinones or any compound, except bupropion or compounds listed under a
509 different schedule, or compounds used within legitimate and approved medical research,
510 structurally derived from 2- Aminopropan-1-one by substitution at the 1-position with Monocyclic
511 or fused polycyclic ring systems, whether or not the compound is further modified in any of the
512 following ways:

513 By substitution in the ring system to any extent with Alkyl, alkylenedioxy, alkoxy, haloalkyl,

514 hydroxyl, or halide Substituents whether or not further substituted in the ring system by one or
515 more other univalent substituents;

516 By substitution at the 3-position with an acyclic alkyl substituent;

517 By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl or methoxybenzyl
518 groups;

519 By inclusion of the 2-amino nitrogen atom in a cyclic structure; or

520 Any other synthetic chemical compound that is a Cannabinoid receptor type 1 agonist as
521 demonstrated by binding studies and functional assays that is not listed in Schedules II, III, IV, and
522 V, not federal Food and Drug Administration approved drug or used within legitimate, approved
523 medical research.

524 (i) Notwithstanding §60A-2-204(d) of this code, if a drug that contains the pharmaceutical
525 composition of crystalline polymorph psilocybin, known as COMP360 or any such trade name
526 approved by the United States Food and Drug Administration, is approved by the United States
527 Food and Drug Administration and scheduled by the Drug Enforcement Administration, it shall be
528 lawful to prescribe, distribute, and market based upon the recommendations of the United States
529 Food and Drug Administration and the United States Drug Enforcement Administration.

NOTE: The purpose of this bill is to add crystalline polymorph psilocybin in the permitted list of distributed and prescribed drugs, if approved by the United States Food and Drug Administration and scheduled by the United States Drug Enforcement Administration.

Strike-throughs indicate language that would be stricken from a heading or the present law and underscoring indicates new language that would be added.